Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.Nature Medicine|September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trialByoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)Xiuning Le, Jyoti D Patel, Elaine Shum, et al.The New England Journal of Medicine|October 23, 2023
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 InsertionsCaicun Zhou, Ke-Jing Tang, Byoung Chul Cho, et al.Nature Medicine|June 13, 2024
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trialAndrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, et al.Signal Transduction and Targeted Therapy|June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutationDan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS StudyMatthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.Pageof 7